selinexor (Xpovio)
Jump to navigation
Jump to search
Indications
- for use in combination with dexamethasone for treatment of adults with relapsed/refractory multiple myeloma*
* at least four prior therapies, resistant to other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, & an anti-CD38 monoclonal antibody[2]
Dosage
- 20 mg tablets
- 60, 80, 100 mg weekly
Monitor
Adverse effects
- leukopenia, neutropenia, thrombocytopenia, anemia
- nausea/vomiting, diarrhea, constipation, decreased appetite, weight loss
- fatigue, fever,
- upper respiratory tract infections
- hyponatremia.
More general terms
References
- ↑ RxNorm
- ↑ 2.0 2.1 Mulcahy N FDA Approves Selinexor for Refractory Multiple Myeloma. Medscape - Jul 03, 2019. https://www.medscape.com/viewarticle/915213